Income Statement Arrowhead Pharmaceuticals, Inc.
Equities
ARWR
US04280A1007
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.38 USD | +1.08% |
|
+4.60% | -3.03% |
| 02-09 | Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400 - Biotechnology | CI |
| 02-09 | Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400 Health Care | CI |
| Fiscal Period: September | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 138M | 243M | 241M | 3.55M | 829M | |||||
Total Revenues | 138M | 243M | 241M | 3.55M | 829M | |||||
Gross Profit | 138M | 243M | 241M | 3.55M | 829M | |||||
Selling General & Admin Expenses, Total | 88.68M | 137M | 109M | 113M | 139M | |||||
Stock-Based Compensation (IS) | - | - | - | - | - | |||||
R&D Expenses | 199M | 284M | 337M | 491M | 593M | |||||
Depreciation & Amortization - (IS) | - | - | - | - | - | |||||
Other Operating Expenses, Total | 287M | 422M | 446M | 605M | 731M | |||||
Operating Income | -149M | -179M | -205M | -601M | 98.35M | |||||
Interest Expense, Total | - | - | -18.33M | -32.35M | -89.36M | |||||
Interest And Investment Income | 6.12M | 5.03M | 15.3M | 22.72M | 37.29M | |||||
Net Interest Expenses | 6.12M | 5.03M | -3.03M | -9.63M | -52.07M | |||||
Other Non Operating Income (Expenses) | 2.07M | 5.2M | 1.54M | -1.75M | 5.26M | |||||
EBT, Excl. Unusual Items | -141M | -168M | -206M | -612M | 51.53M | |||||
Gain (Loss) On Sale Of Investments | - | -4.43M | - | - | - | |||||
Asset Writedown | - | - | - | - | - | |||||
In Process R&D Expenses | - | - | - | - | - | |||||
Insurance Settlements | - | - | - | - | - | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | -141M | -173M | -206M | -612M | 51.53M | |||||
Income Tax Expense | 2K | 3.78M | 2.78M | -2.77M | 21.42M | |||||
Earnings From Continuing Operations | -141M | -176M | -209M | -610M | 30.11M | |||||
Net Income to Company | -141M | -176M | -209M | -610M | 30.11M | |||||
Minority Interest | - | 431K | 4M | 10.2M | -31.74M | |||||
Net Income - (IS) | -141M | -176M | -205M | -599M | -1.63M | |||||
Net Income to Common Incl Extra Items | -141M | -176M | -205M | -599M | -1.63M | |||||
Net Income to Common Excl. Extra Items | -141M | -176M | -205M | -599M | -1.63M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -1.36 | -1.67 | -1.92 | -5 | -0.01 | |||||
Basic EPS - Continuing Operations | -1.36 | -1.67 | -1.92 | -5 | -0.01 | |||||
Basic Weighted Average Shares Outstanding | 104M | 105M | 107M | 120M | 134M | |||||
Net EPS - Diluted | -1.36 | -1.67 | -1.92 | -5 | -0.01 | |||||
Diluted EPS - Continuing Operations | -1.36 | -1.67 | -1.92 | -5 | -0.01 | |||||
Diluted Weighted Average Shares Outstanding | 104M | 105M | 107M | 120M | 134M | |||||
Normalized Basic EPS | -0.85 | -0.99 | -1.17 | -3.11 | 0 | |||||
Normalized Diluted EPS | -0.85 | -0.99 | -1.17 | -3.11 | 0 | |||||
American Depositary Receipts Ratio (ADR) | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | |||||
Supplemental Items | ||||||||||
EBITDA | -141M | -168M | -193M | -582M | 122M | |||||
EBITA | -147M | -177M | -203M | -599M | 100M | |||||
EBIT | -149M | -179M | -205M | -601M | 98.35M | |||||
EBITDAR | -131M | -152M | -173M | -566M | 139M | |||||
Effective Tax Rate - (Ratio) | -0 | -2.19 | -1.35 | 0.45 | 41.56 | |||||
Current Domestic Taxes | 2K | 304K | 2.78M | 523K | 21.38M | |||||
Current Foreign Taxes | - | 3.48M | - | -3.29M | 35K | |||||
Total Current Taxes | 2K | 3.78M | 2.78M | -2.77M | 21.42M | |||||
Normalized Net Income | -88.03M | -105M | -125M | -373M | 463K | |||||
Interest on Long-Term Debt | - | - | - | 9.32M | 63.32M | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | 78.64M | 122M | 89.13M | 96.76M | 122M | |||||
Research And Development Expense From Footnotes | 206M | 297M | 353M | 506M | 607M | |||||
Net Rental Expense, Total | 10.04M | 15.86M | 19.68M | 16.69M | 16.51M | |||||
Imputed Operating Lease Interest Expense | - | - | 12.41M | 6.99M | 14.79M | |||||
Imputed Operating Lease Depreciation | - | - | 7.27M | 9.7M | 1.72M | |||||
Stock-Based Comp., R&D Exp. (Total) | 25.74M | 32.37M | 34.33M | 33.59M | 32.58M | |||||
Stock-Based Comp., G&A Exp. (Total) | 50.93M | 88.52M | 43.8M | 40.38M | 30.78M | |||||
Stock-Based Comp., Other (Total) | - | 1K | - | - | - | |||||
Total Stock-Based Compensation | 76.67M | 121M | 78.13M | 73.97M | 63.37M |
- Stock Market
- Equities
- ARWR Stock
- Financials Arrowhead Pharmaceuticals, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















